Hide table of contents

Background

A little over a year ago, my employer submitted trial data to the FDA relating to the efficacy of one of the company's diagnostic products that was, at that time, already being used under an EUA (Emergency Use Authorization). The new data involved a direct performance comparison between the company's product and a class of competing products already on the market. We planned to publish the data, but shortly before doing so, we shared it with the FDA.

Per my employer's analysis, the trial showed that those competing products had severe performance problems in real clinical practice (that had gone undetected in previous trials of them that used contrived samples or cherry-picked non-representative patients). This had implications not only for clinical practice but also for the FDA's approval process, since the FDA had been evaluating new diagnostics of the sort that my employer had developed by requiring concordance tests between them and this class of competing products that - we now argued - frequently got wrong results. As a consequence, we argued, tests that were actually more accurate were at risk of being unfairly rejected, while this inferior class of diagnostics we were competing with would be easily permitted on the market.

(I should note here that the science is disputed and that many studies exist that reach opposing conclusions. Anyway, the meat of the story, at least to my mind, is what happened next...)

According to the various executives who've told me the story, upon receiving this data, FDA staff spoke to our CEO on the phone and demanded that we not publish the data, threatening, explicitly, that if it were published they would respond by revoking our existing EUA for our product, thus destroying our existing business. This was after we had already shared the data privately with the FDA, so this wasn't a discussion about what the FDA would hypothetically do if presented with this data; it was specifically about the consequences of publishing it for others to read. We assume that the threat was motivated by fear that data like ours would cast doubt on the FDA's previous decisions about which products to approve in our field.

(I should note here that I was not a direct witness to this threat, but I have a direct witness account of it in writing and believe it to be truthful - although I am not entirely sure. We don't have the threat itself in writing, since it was made over the phone. For what it's worth, the only person with experience working for the FDA who I've chatted to about this confirmed that the FDA likes to keep discussions with companies over the phone specifically to avoid a paper trail - so that part of our CEO's story checks out.)

Eventually we did in fact publish (presumably in defiance of the threat), but the company never spoke publicly about the FDA threatening us (presumably because we're afraid that doing so will trigger retaliation or cause us to receive less favourable treatment from the FDA in future). I have tried since then, unsuccessfully, to persuade the CEO to speak out - either to the press, or to some FDA HR or internal affairs department or to some other federal law enforcement agency that could take action against the FDA staff who made the threat. I have not succeeded.

The arguments for and against speaking out

I'm trying to figure out what to do next. The company's management is not keen to pick this fight and have tried to persuade me that it is a waste of time and energy for me to be thinking about. To me, it seems like shrewd action here could potentially save huge numbers of lives. To summarise our disagreements...

How many people do we expect to be seriously harmed if this behaviour is left unpunished?

My take: Potentially, vast numbers! If these FDA staff were willing to use this tactic against us, it's reasonable to expect they'll do it again whenever they see similar political/reputational/work-avoidance advantages to doing so. And such suppression of trial data has the potential to cause mass death; the most famous case I know of where non-publication of clinical trial data was blamed for subsequent deaths is the use of lorcainide on people who have had heart attacks, where initial trial data from 1980 that suggested it actually made them more likely to die was not published, and doctors in the US didn't realise and stop prescribing it until they'd killed 100000 people. And that was merely one case of a voluntary decision by researchers not to publish inconclusive data that they didn't trust the conclusions of. Repeated suppression by a regulator specifically of credible trial data that casts doubt on their past approvals could thus be expected to regularly have severe consequences like this.

Management's take: Thinking there are lots of lives at stake here is wild speculation. We don't know these kind of threats have ever been made to anyone other than us. We ultimately called the FDA's bluff and published our data despite the threats we received, so this tactic doesn't seem like it's even very effective at suppressing data. And the spectacular bad consequences of data on lorcainide not being published are clearly exceptional, which is exactly why lorcainide is famous; decisions not to publish trial data happen all the time, and obviously don't normally kill 100000 people. Nor would suppression by the FDA typically have such consequences, even if it were widespread.

Would the public and/or a regulatory or disciplinary body even see this behaviour as wrong and worthy of punishment?

My take: Of course! The FDA is meant to make approval decisions based on safety and efficacy. Here they explicitly threatened to make those decisions conditional on us burying trial data. That's contrary to the FDA's mission, a violation of the First Amendment, and almost certainly some sort of criminal corruption. Most people will see this the same way as me: clinical trial data should be published, and any story about it being deliberately buried deserves to be a scandal.

Management's take: Even if you convince people this really happened, nobody is going to care. It's not like the FDA reviewer was soliciting bribes; without some kind of direct personal gain for the FDA staff involved, nobody's going to see this as corrupt. Furthermore the FDA staff involved can simply argue that they didn't want the research published because they felt the methodology was flawed and the conclusions were wrong, and most people, including anyone who might take disciplinary action against them, will see that as perfectly reasonable.

(For what it's worth, the previously mentioned FDA insider I've spoken to about this was of the view that if it were proven this would be a scandal and should lead to the FDA firing the staff involved.)

Even if this would be seen as wrong, is it worth trying to take action without hard evidence?

My take: Of course! Just like with any crime or act of wrongdoing that you witness, you don't necessarily report it (to authorities, or to the press) with proof already in hand. You make the allegation, and leave it to the cops / HR people / journalists / etc. to investigate that allegation. Maybe other FDA staff who were present for the meeting but uncomfortable with the threat being made will snitch when asked about it. Maybe they emailed each other about it and there's an internal paper trail! An investigation has at least a fighting chance of finding proof, and that's enough to justify starting one.

Management's take: The only evidence we have is the word of our own staff. There are no recordings and no paper trail. Without hard evidence, nobody is even going to bother starting an investigation into this.

How much scope is there for speaking out to be counterproductive

My take: Not much. Even if an investigation fails to find any evidence, it should still instil fear in the guilty parties and deter them from making such threats in future - which is still a good outcome. And any public reporting about this threat, even without proof, may encourage other companies that have received similar threats, especially from the same individual FDA employees, to speak up.

Management's take: Lots. The FDA is a household name that people trust; we are not. The likely outcome of any attempt by us to take action on this is that it ends up in the press, the reporting makes us look like liars with a bad product, the FDA retaliates against us by refusing approvals on future products and thereby wrecks our company, and anyone else who has a similar experience to us in future and thinks of speaking out will look at the fate we suffered and think again.

My questions

With the above disagreements in mind, I'd like to seek some advice, especially from people with experience of the US medical industry, and most especially from anyone with direct experience of dealing with the FDA.

  1. Is it normal for the FDA to try to control what trial data does and doesn't get published via threats of regulatory retaliation? Have you heard similar stories of this? Indeed, do you find the claim plausible, or think that our CEO must be lying to me for some reason?
  2. Is fighting to get the FDA staff involved disciplined a worthwhile cause and potentially a way to save many lives, like I think it is? Or would I be wasting time and energy and putting my employer at risk with no real prospect of doing any good, as the company thinks? If you had to put an expected value in QALYS or lives saved on me or my employer pursuing this, what would it be?
  3. If I were to leak what I know against the company's wishes, who should I leak to?
    1. The press? If so, which journalists or outlets?
    2. An internal team at the FDA? If so, who? There's an Office of Internal Affairs at the FDA; would they investigate an allegation like this?
    3. Some kind of federal law enforcement agency? If so, who? The GAO? The FBI? Who would be interested in this?
  4. Are there any other people or organisations you'd suggest talking to for advice on this?
  5. Besides "leak what I know to somebody with the ability to investigate further" and "do nothing", are there any other courses of action I'm failing to consider that could do some good?

And finally, putting it all together: what would you do in my place, and why?

Comments13


Sorted by Click to highlight new comments since:

There are law firms in the DC area that specialize in whistleblower protection. These are often used for cases where there is some financial reward to the whistleblower, which may not be relevant here (though I certainly am not an expert!!). However, I would suspect that they may have the general expertise, discretion, connections, and playbook to handle something like this. It may be a good place to start. Google keywords would be something like "DC government whistleblower law firm."

(Also worth noting that lawyers take client confidentiality very seriously)

I want to know if you can find more people companies that have experienced a similar thing with the FDA. 

Is there a reddit or discussion forum where people discuss and commiserate about FDA threats like this one? Can you find people there, and then verify that they / their experiences are real?

As a naive outsider, it seems to me like all of the specific actions you suggest would be stronger and more compelling if you can muster a legitimate claim that this is a pattern of behavior and not just a one-off. An article with one source making an accusations is more than 3x less credible than an article with 3 sources making the same accusation, for instance.

And if this is just a one-off, then it seems a lot less concerning, and taking action seems much less pressing. (Though it seems much easier to verify that this is a pattern, by finding other people in a similar situation to yours, than to verify that it isn't, since there are incentives to be quiet about this sort of thing).

And if this is just a one-off, then it seems a lot less concerning, and taking action seems much less pressing. (Though it seems much easier to verify that this is a pattern, by finding other people in a similar situation to yours, than to verify that it isn't, since there are incentives to be quiet about this sort of thing).


Is this the case? Often the reaction to the 'first transgression' will determine whether or not to do future ones--if people let it slide, then probably they don't care that much, whereas if they react strongly, it's important to repent and not do again.

And when there are patterns of behavior, especially in cases with significant power dynamics, it seems unlikely that you'd be able to collect such stories (in a usable way) without there being a prominent example of someone who shared their story and it went well for them. 

I would suggest contacting a congressperson who sits on a committee with oversight of the FDA. Your best bet on a response is if your own representative sits on one of these committees:

  • Senate Committee on Health, Education, Labor Pensions
  • House Committee on Energy and Commerce Subcommittee in Health

If your representative is not on either committee, you can try Chair Patty Murray's office for the Senate or Chair Anna Eshoo for the House. The Committees themselves also have full time staff who can sometimes be found on LinkedIn.

It would be a good idea to ask them about whistleblower protection, especially if you cannot hire an attorney, which was a suggestion.

Making this suggestion for a few reasons: if it's pervasive at the FDA, their Internal Affairs may be limited. Though damaging, this isn't a crime so law enforcement isn't appropriate. If contacting Congress goes nowhere, you could consider media, but their incentives will be attention, not necessarily resolution and definitely not your protection.

Disclaimer: I am just a random onlooker with no particular relevant expertise.

In your place, I suspect I would do what you're doing, but maybe with less interest in my employer's perspective (not that you should follow my putative example). The FDA is being completely corrupt here and in a completely banal way, of course it must receive punishment if at all possible.

I would be surprised if any journalist wanted to run with this story given the lack of proof (due to intentional lack of paper trail), or if this report alone caused anything in particular. However, it is still a valuable contribution to a body of evidence on the topic, and you could end up unknowingly corroborating other reports on the same topic. 

Re: journalists: Yeah you could probably just send this to several journalists, especially watchdog-y publications like ProPublica and Motherjones. At the very least they will be able to contact you in the future if they decide to run a story on the topic.

Re: Internal affairs: maybe just call them anonymously (VOIP?) and ask if this is indeed the kind of thing they care about?

Anyway, I'm sending you wishes of strength and wellness. Godspeed. 

Also, if I were you / your employer I would certainly start secretly recording any correspondence with the government.

This is a crime in a lot of places. I would not do it unless a lawyer in your jurisdiction has OK'd it 

You can definitely get access to Glenn Greenwald and this is definitely something he'd be willing to report on.

But then you lose all mainstream credibility; it just gets written off as a fringe conspiracy theory. 

Is the Edward Snowden strategy applicable here?

I'm guessing this was downvoted due to unclarity, maybe expand on what you mean?

Something like anonymously contacting journalists.

Curated and popular this week
 ·  · 20m read
 · 
Advanced AI could unlock an era of enlightened and competent government action. But without smart, active investment, we’ll squander that opportunity and barrel blindly into danger. Executive summary See also a summary on Twitter / X. The US federal government is falling behind the private sector on AI adoption. As AI improves, a growing gap would leave the government unable to effectively respond to AI-driven existential challenges and threaten the legitimacy of its democratic institutions. A dual imperative → Government adoption of AI can’t wait. Making steady progress is critical to: * Boost the government’s capacity to effectively respond to AI-driven existential challenges * Help democratic oversight keep up with the technological power of other groups * Defuse the risk of rushed AI adoption in a crisis → But hasty AI adoption could backfire. Without care, integration of AI could: * Be exploited, subverting independent government action * Lead to unsafe deployment of AI systems * Accelerate arms races or compress safety research timelines Summary of the recommendations 1. Work with the US federal government to help it effectively adopt AI Simplistic “pro-security” or “pro-speed” attitudes miss the point. Both are important — and many interventions would help with both. We should: * Invest in win-win measures that both facilitate adoption and reduce the risks involved, e.g.: * Build technical expertise within government (invest in AI and technical talent, ensure NIST is well resourced) * Streamline procurement processes for AI products and related tech (like cloud services) * Modernize the government’s digital infrastructure and data management practices * Prioritize high-leverage interventions that have strong adoption-boosting benefits with minor security costs or vice versa, e.g.: * On the security side: investing in cyber security, pre-deployment testing of AI in high-stakes areas, and advancing research on mitigating the ris
saulius
 ·  · 22m read
 · 
Summary In this article, I estimate the cost-effectiveness of five Anima International programs in Poland: improving cage-free and broiler welfare, blocking new factory farms, banning fur farming, and encouraging retailers to sell more plant-based protein. I estimate that together, these programs help roughly 136 animals—or 32 years of farmed animal life—per dollar spent. Animal years affected per dollar spent was within an order of magnitude for all five evaluated interventions. I also tried to estimate how much suffering each program alleviates. Using SADs (Suffering-Adjusted Days)—a metric developed by Ambitious Impact (AIM) that accounts for species differences and pain intensity—Anima’s programs appear highly cost-effective, even compared to charities recommended by Animal Charity Evaluators. However, I also ran a small informal survey to understand how people intuitively weigh different categories of pain defined by the Welfare Footprint Institute. The results suggested that SADs may heavily underweight brief but intense suffering. Based on those findings, I created my own metric DCDE (Disabling Chicken Day Equivalent) with different weightings. Under this approach, interventions focused on humane slaughter look more promising, while cage-free campaigns appear less impactful. These results are highly uncertain but show how sensitive conclusions are to how we value different kinds of suffering. My estimates are highly speculative, often relying on subjective judgments from Anima International staff regarding factors such as the likelihood of success for various interventions. This introduces potential bias. Another major source of uncertainty is how long the effects of reforms will last if achieved. To address this, I developed a methodology to estimate impact duration for chicken welfare campaigns. However, I’m essentially guessing when it comes to how long the impact of farm-blocking or fur bans might last—there’s just too much uncertainty. Background In
 ·  · 7m read
 · 
Introduction This payout report covers the Animal Welfare Fund's grantmaking from January 1, 2025 to March 31, 2025 (3 months). It follows the previous October–December 2024 payout report. As mentioned in the 2024 review and the previous payout report, the Animal Welfare Fund  (AWF) made a conscious decision to increase transparency and prioritize more frequent communications about our work. As part of those efforts, we've resumed regular publication of detailed payout reports after previously reducing our public reporting to focus fund manager capacity on grant evaluations. With additional support now in place, we've streamlined our reporting process to provide comprehensive information about our grants and their intended impact. Given that these are recent grants, outcome data will not be included in the initial payout reports. We plan to share these reports quarterly to keep the community informed of our grantmaking activities. Update to private grant reporting While we aim to increase the AWF’s transparency, we also recognize the important benefits that private grants provide: protecting organizations from government harassment, reducing risks of damage to strategic relationships between organizations and industry players, and maintaining security for sensitive work. We don't want strong applicants to be discouraged from applying due to concerns about public reporting and therefore miss out on the impact they could have.  To balance the risks that public reporting has with the benefits of transparency, we are establishing a new approach for private reporting: private grants will be included within payout reports, but we will include them in an anonymized format (e.g. “$350,000 - across three organizations working on fish welfare”, or “$120,000 - welfare improvements in East Asia”), and in some cases, still only list the amount and not the purpose, (e.g. “$50,000 - private grant”). The latter will only be done if we think disclosing details poses a risk of har